About the job
Axsome Therapeutics develops and delivers new treatments for central nervous system (CNS) disorders. The company focuses on areas where patient needs remain unmet, aiming to improve care for individuals living with serious neurological and psychiatric conditions.
The current product pipeline features FDA-approved therapies for major depressive disorder, excessive daytime sleepiness linked to narcolepsy, and migraine. Additional late-stage programs target a broad range of brain health challenges, reaching millions across the United States.
Focus on Patient Impact
Axsome’s work centers on advancing therapies that address significant gaps in care. The goal is to help patients and families manage complex CNS conditions and improve quality of life.
Therapeutic Areas
- Major depressive disorder
- Narcolepsy-related excessive daytime sleepiness
- Migraine
- Other late-stage neurological and psychiatric programs
